Difficulty: Medium
Average Score: 82%
Practice
Which drug works as a competitive reversible inhibitor of DPP-4, reducing enzymatic inactivation of the incretin hormones, GLP-1 and GIP?
Correct answer
D
Rationale
DPP-4 inhibitors enhance incretin hormone activity (GLP-1 and GIP), which boosts insulin secretion and reduces glucagon levels in a glucose-dependent manner, aiding glycemic control in type 2 diabetes. Sitagliptin is a DPP-4 inhibitor, competitively and reversibly blocking the enzyme to prolong incretin effects. Metformin primarily reduces hepatic glucose production and improves insulin sensitivity, not a DPP-4 inhibitor. Pioglitazone is a PPAR-gamma agonist enhancing insulin sensitivity, while Nateglinide is a meglitinide stimulating insulin release via potassium channels. Only Sitagliptin matches the described mechanism, making D correct. This distinction is vital as DPP-4 inhibitors offer a unique approach to diabetes management, minimizing hypoglycemia risk compared to other classes.